SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma inks manufacturing sublicense agreement with GARDP

12 Sep 2023 Evaluate

Orchid Pharma has entered into a manufacturing sublicense agreement with Global Antibiotic Research & Development Partnership (GARDP) to manufacture Cefiderocol- an antibiotic to treat certain Gram-negative infections.

This agreement is a critical step in an ambitious project by Shionogi & Co. (Shionogi), GARDP, and the Clinton Health Access Initiative (CHAI) that aims to provide access to Cefiderocol in a number of predominantly low and middle-income countries.

Orchid Pharma, established as an export-oriented unit (EOU), is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing.


Orchid Pharma Share Price

564.10 -3.40 (-0.60%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×